FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf ProspectusAccesswire • 11/06/23
FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly NuAccesswire • 10/23/23
Dr. Raza Bokhari, Former Executive Chairman and CEO of FSD Pharma, Provides Litigation UpdateNewsfile Corp • 10/16/23
FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of JusticeAccesswire • 10/04/23
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well ToleratedAccesswire • 09/18/23
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)Business Wire • 08/25/23
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023Accesswire • 08/15/23
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification DrinkAccesswire • 08/02/23
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201Business Wire • 07/17/23
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stockBusiness Wire • 07/10/23
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of DirectorsBusiness Wire • 07/04/23
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of ShareholdersBusiness Wire • 06/30/23
DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLIONPRNewsWire • 06/21/23
FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse TechnologyBusiness Wire • 06/20/23
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of DirectorsBusiness Wire • 05/25/23
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and DistributionBusiness Wire • 05/12/23
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second CohortBusiness Wire • 05/10/23
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple SclerosisBusiness Wire • 04/17/23
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023Business Wire • 04/12/23